DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The prognosis of patients with "high-grade B cell lymphoma with cellular myelocytomatosis
(MYC) and B cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 (BCL6) rearrangements" (double
hit (DH)/triple hit (TH)-HGBL) with rituximab-CHOP (R-CHOP) is dismal as compared to patients
with diffuse large B cell lymphoma (DLBCL) without MYC, BCL2 and/or BCL6 rearrangements.
Currently, there is no other standard first line treatment for these patients. Dose Adjusted
- Etoposide Prednisone Vincristine Cyclophosphamide Doxorubicin - Rituximab (DA-EPOCH-R) and
nivolumab are both feasible treatments. Nivolumab may induce auto-immune reactions.
DA-EPOCH-R may induce more hematological toxicity than R-CHOP. The hypothesis is that
addition of nivolumab to DA-EPOCH-R will contribute to increased survival.
Phase:
Phase 2
Details
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland